Close Menu

gastrointestinal disease

With clinical sequencing data for almost 400 appendiceal cancer cases, researchers identified somatic differences in individuals diagnosed with the disease before the age of 50.

Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics. 

To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.

The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.

By participating in the project, the company, located in Tokyo, hopes to improve its cloud-based data management services while winning over new customers.

The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.

The FDA-cleared panel includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, and Cryptosporidium.

The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.

Applied BioCode said that it now has access to higher volume laboratories that use the Roche MagNa Pure 96 System for sample extraction.

Common non-coding variants, along with rarer coding alterations, appear to contribute to a developmental disease with bowel and other gastrointestinal symptoms.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.